Cancer Treatment Results  Survival Rates Cancer Treatments / Therapy Results

Click here to go back to your search results.

Melanoma treatment details. Immunotherapy. St. Luke's Medical Center, Bethlehem, PA, United States

Survival: 9.6 months
Toxicity Grade: 4
Treatments: Immunotherapy
Country: United States
City/State/Province: Bethlehem, PA
Hospital: St. Luke's Medical Center
Journal: Link
Date: 9/2007

Patients: This phase II trial involved twenty-six patients with metastatic melanoma. There were 12 men and 14 women. The median age was 45 years, ranging from 28-70. The patientsí disease had progressed during or after they were treated with biochemotherapy: cisplatin, vinblastine, dacarbazine, interleukin-2 and interferon alfa-2b.

Treatment: Patients were treated with an infusion of high-dose bolus interleukin-2.

Toxicity: Grade 3 and 4 toxicities included anemia, leukopenia, thrombocytopenia, tachycardia, hypotension, nausea, vomiting, diarrhea, renal and hepatic abnormalities (oliguria and increased bilirubin), infection, rash, and fatigue/delirium. Each of these occurred in less than 10 patients, except for hepatic (liver) abnormality, which occurred in 13 patients.

Results: The median overall survival was 9.6 months (41.9 weeks). The median progression-free survival was 10 weeks.

Correspondence: Dr. Sanjiv S. Agarwala

E-mail to a Friend Email Physician More Information